WO2026028089 - COMPOSITIONS AND METHODS FOR THE TREATMENT OF LYSOSOMAL ACID LIPASE DEFICIENCY (LAL-D)
National phase entry is expected:
Publication Number
WO/2026/028089
Publication Date
05.02.2026
International Application No.
PCT/IB2025/057651
International Filing Date
28.07.2025
Title **
[English]
COMPOSITIONS AND METHODS FOR THE TREATMENT OF LYSOSOMAL ACID LIPASE DEFICIENCY (LAL-D)
[French]
COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT D'UN DÉFICIT EN LIPASE D'ACIDE LYSOSOMALE (LAL-D)
Applicants **
NOVARTIS AG
Inventors
CHEN, Feng Graf
FLYNN, Jonathan Robert
LIN, Amy Hsiu-Ti
MAO, Xiaochong
WEINMANN, Jonas
Priority Data
63/676,736
29.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6485 | |
| EPO | Filing, Examination, Granting | 47718 | |
| Japan | Filing, Examination, Granting | 3510 | |
| South Korea | Filing, Examination, Granting | 4822 | |
| USA | Filing, Examination, Granting | 20040 |
Total:
82,575
Contact Us
Abstract[English]
The present disclosure relates to gene therapy compositions and methods for the preparation and use thereof, for the treatment of Lysosomal Acid Lipase Deficiency (LAL-D) disorders, such as Wolman Disease and cholesterol ester storage disease (CESD).[French]
La présente divulgation concerne des compositions de thérapie génique et leurs procédés de préparation et d'utilisation, pour le traitement de troubles liés au déficit en lipase acide lysosomale (LAL-D), tels que la maladie de Wolman et la maladie de stockage des esters du cholestérol (CESD).